[1]侯丁丁,赵 力.初始不可切除同时性结直肠癌肝转移的治疗策略[J].医学信息,2021,34(04):60-63.[doi:10.3969/j.issn.1006-1959.2021.04.016]
　HOU Ding-ding,ZHAO Li.Treatment Strategy of Primary Unresectable Synchronous Liver Metastases of Colorectal Cancer[J].Medical Information,2021,34(04):60-63.[doi:10.3969/j.issn.1006-1959.2021.04.016]
点击复制

初始不可切除同时性结直肠癌肝转移的治疗策略()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年04期
页码:
60-63
栏目:
综述
出版日期:
2021-02-15

文章信息/Info

Title:
Treatment Strategy of Primary Unresectable Synchronous Liver Metastases of Colorectal Cancer
文章编号:
1006-1959（2021）04-0060-04
作者:
侯丁丁; 赵 力
（清华大学第一附属医院普外科，北京 100016）
Author(s):
HOU Ding-ding; ZHAO Li
(Department of General Surgery,the First Hospital of Tsinghua University,Beijing 100016,China)
关键词:
结直肠癌肝转移; 转化治疗; 原发灶切除术; 维持治疗
Keywords:
olorectal cancer liver metastasis; Conversion therapy; Primary tumor resection; Maintenance therapy
分类号:
R735.3+4
DOI:
10.3969/j.issn.1006-1959.2021.04.016
文献标志码:
A
摘要:
初始不可切除的同时性结直肠癌肝转移患者的治疗包括转化治疗、原发灶切除及术后维持治疗方案三个阶段。FOLFOXIRI联合靶向药物具有高转化率，应作为一线治疗方案，并注意其毒副作用。对于转化后肝转移灶缓解并处于稳定状态，但始终无法到达无疾病状态，尽管原发灶无出血、穿孔及梗阻等肿瘤相关并发症，仍倾向选择适合适的患者行原发灶切除术。术后继续应用卡培他滨和贝伐珠单抗方案行维持治疗，能最大程度提高患者的总生存期，并提高患者生活质量。本文就转化治疗、原发灶切除及术后维持治疗的策略进行综述。
Abstract:
Primary unresectable synchronous liver metastases of colorectal cancer had included three stages of treatment which involved conversion therapy, primary tumor resection and postoperative maintenance therapy.FOLFOXIRI combined with targeted drugs had a high conversion rate and should be used as a first-line treatment regimen with attention to its toxic and side effects. For liver metastases after transformation, they are relieved and in a stable state, but they cannot reach a disease-free state. Although the primary tumor has no tumor-related complications such as hemorrhage, perforation, and obstruction, there is still a tendency to select suitable patients for primary tumor resection.Continuing the use of capecitabine and bevacizumab for maintenance treatment after surgery can maximize the overall survival of the patient and improve the quality of life of the patient.This article reviews the strategies of conversion therapy, primary tumor resection and postoperative maintenance therapy.

参考文献/References:

[1]中华医学会外科学分会胃肠外科学组,中华医学会外科学分会结直肠外科学组,中国抗癌协会大肠癌专业委员会,等.中国结直肠癌肝转移诊断和综合治疗指南(2018版)[J].中华消化外科杂志,2018,17(6):527-539. [2]中国医疗保健国际交流促进会,结直肠癌肝转移分会.中国医促会结直肠癌肝转移分会结直肠癌肝转移MDT诊治共识(讨论版)[J].肝癌电子杂志,2017,4(2):1-12. [3]Falcone A,Ricci S,Brunetti I,et al.Phase Ⅲ trial of infusional fluorouracil,leucovorin,oxaliplatin,and irinotecan(FOLFOXIRI)compared with infusional fluorouracil, leucovorin, and irinotecan(FOLFIRI)as first-line treatment for metastatic colorectal cancer:the Gruppo Oncologico Nord Ovest[J].J Clin Oncol,2007,25(13):1670-1676. [4]Loupakis F,Cremolini C,Masi G,et al.Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer[J].N Engl J Med,2014,371(17):1609-1618. [5]张雯.FOLFOXIRI联合贝伐珠单抗研究进展及其在结直肠癌肝转移治疗中的应用思考[J].肝癌电子杂志,2019,6(2):5-9. [6]Cremolini C,Antoniotti C,Rossini D,et al.Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer(TRIBE2):a multicentre,open-label,phase 3,randomised,controlled trial[J].Lancet Oncol,2020,21(4):497-507. [7]徐达,邢宝才.结直肠癌肝转移围手术期化疗[J].中华胃肠外科杂志,2019,22(4):321-328. [8]Leal F,Ferreira FP,Sasse AD.FOLFOXIRI Regimen for Metastatic Colorectal Cancer:A Systematic Review and Meta-Analysis[J].Clin Colorectal Cancer,2017,16(4):405-409. [9]蔡月,邓儒,胡华斌,等.改良剂量的FOLFOXIRI化疗方案(氟尿嘧啶、奥沙利铂、伊立替康)治疗结直肠癌的安全性和初步疗效分析[J].中华胃肠外科杂志,2018,21(9):1045-1050. [10]张音洁,王晰程,李健,等.三药联合方案治疗晚期转移性结直肠癌的疗效和安全性比较[J].中国肿瘤临床,2019(4):178-183. [11]李斌奎,陈功.结直肠癌肝转移诊疗新理念与新策略[J].中华转移性肿瘤杂志,2018,1(3):52-61. [12]Tarantino I,Warschkow R,Worni M,et al.Prognostic Relevance of Palliative Primary Tumor Removal in 37,793 Metastatic Colorectal Cancer Patients:A Population-Based,Propensity Score-Adjusted Trend Analysis[J].Ann Surg,2015,262(1):112-120. [13]Maroney S,de Paz CC,Reeves ME,et al.Benefit of Surgical Resection of the Primary Tumor in Patients Undergoing Chemotherapy for Stage IV Colorectal Cancer with Unresected Metastasis[J].J Gastrointest Surg,2018,22(3):460-466. [14]Alawadi Z,Phatak UR,Hu CY,et al.Comparative effectiveness of primary tumor resection in patients with stage Ⅳ colon cancer[J].Cancer,2017,123(7):1124-1133. [15]Moritani K,Kanemitsu Y,Shida D,et al.A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage Ⅳ colorectal cancer:JCOG1007(iPACSstudy)[J].Jpn J Clin Oncol,2020,50(1):89-93. [16]周才进,徐飞鹏,欧雯婷,等.快速康复外科在直肠癌腹腔镜根治术患者围手术期的应用[J].山东医药,2018,58(34):57-59. [17]方琳,刘超,张纯慧,等.转移性结直肠癌维持治疗的研究现状与治疗策略[J].实用肿瘤学杂志,2019,33(2):173-178. [18]Pfeiffer P,Sorbye H,Qvortrup C,et al.Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer:The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group[J].Clin Colorectal Cancer,2015,14(3):170-176. [19]向芳,谢小军,殷先利.西妥昔单抗用于全RAS野生型晚期结直肠癌患者维持治疗的临床研究[J].实用医院临床杂志,2017,14(5):192-195. [20]Tournigand C,Chibaudel B,Samson B,et al.Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer(GERCOR DREAM;OPTIMOX3):a randomised,open-label,phase 3 trial[J].Lancet Oncol,2015,16(15):1493-1505. [21]Simkens LH,van Tinteren H,May A,et al.Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer(CAIRO3):a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group[J].Lancet,2015,385(9980):1843-1852. [22]罗鑫,叶晓芬,蔡映云,等.结直肠癌和非小细胞肺癌患者发生贝伐珠单抗相关蛋白尿事件的危险因素分析[J].药物不良反应杂志,2019,21(2):118-122. [23]张宁刚,王育生,李秀秀,等.贝伐珠单抗联合不同化疗方案治疗晚期结直肠癌的不良反应[J].药物不良反应杂志,2017,19(5):346-352.

更新日期/Last Update: 1900-01-01